Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Takhzyro (lanadelumab-flyo) for the Prevention of Hereditary Angioedema

Drug Name

Takhzyro™ (lanadelumab-flyo)

Developer

Shire, Dyax

Therapy Class

Fully human monoclonal antibody

Current Indication

Hereditary angioedema

Market Sector

Genetic diseases

Development Status

Approved in the US and Canada
Expand

Go Top